Cisplatin‐induced acute renal failure is ameliorated by erdosteine in a dose‐dependent manner

Abstract

The aim of this study was to investigate the optimum dosage of erdosteine to ameliorate cisplatin-induced nephrotoxicity. Three different doses of erdosteine at 25, 50 and 75 mg kg(-1) were studied in rats. Intraperitoneal administration of 7 mg kg(-1) cisplatin led to acute renal failure, as indicated by kidney histology and increases in plasma creatinine and blood urea nitrogen (BUN) levels. At 5 days after cisplatin injection the BUN level was increased significantly from 15.1 +/- 4.3 to 126.7 +/- 152.6 mg dl(-1) and plasma creatinine levels increased from 0.37 +/- 0.005 to 1.68 +/- 1.9 mg dl(-1). When the rats were administered 50 and 75 mg kg(-1) erdosteine 24 h before cisplatin injection that was continued until sacrifice (total of 6 days), the BUN and creatinine levels remained similar to control levels and the grade of histology was similar. Erdosteine at doses of 50 and 75 mg kg(-1) ameliorates cisplatin-induced renal failure. The optimum dose of erdosteine may be 50 mg kg(-1) in this study.

Erdosteine protects HEI-OC1 auditory cells from cisplatin toxicity through suppression of inflammatory cytokines and induction of Nrf2 target proteins

“…Furthermore, oral treatment with erdosteine, attenuated the increase in serum creatinine level following an intraperitoneal injection of cisplatin , and prevented cisplatin-induced in vivo nephrotoxicity and hepatic oxidative injury in rats (Koc et al 2005;Ozyurt et al 2004). In addition, there is in vivo evidence of the protective effect of erdosteine against cisplatin in rats ( Kalcioglu et al 2005) and guinea pigs (Waissbluth et al 2012).…”

“…5 of erdosteine metabolites for various drug-induced conditions including cardiotoxicity, hepatotoxicity, nephrotoxicity, and ischemia-reperfusion injury (Erarslan et al 2011;Fadillioglu et al 2003;Lee et al 2010;Ozyurt et al 2004;Selcoki et al 2007). Furthermore, oral treatment with erdosteine, attenuated the increase in serum creatinine level following an intraperitoneal injection of cisplatin , and prevented cisplatin-induced in vivo nephrotoxicity and hepatic oxidative injury in rats (Koc et al 2005;Ozyurt et al 2004).…”

Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives

“…Intraperitonealadministration of cisplatin atasingle doseo f7mg/kg led tothe developmentof ARF in rats whichwascharacterized bypronounced elevation of bothp lasmac reatinine and blood ureanitrogen levels and akidneyhistologyw hichconfirmed the insultt o the organ [71,72].Itw asfound thatARF mayhavep receded the completeattainmentof renaltubularnecrosis suggesting thatr enaltubularobstruction wasnott he primary driveru nlike othermodels.Owing toi ts distribution tol ivert issue,itmayalsoi mpart hepaticfunctionalchanges.…”

Erdosteine modulates radiocontrast‐induced hepatotoxicity in rat

“…The erdosteine was obtained from a drug company (Ilsan, Istanbul, Turkey), dissolved in distilled water with NaHCO 3 and administered orally once a day for 2 days at a dose of 25 mg kg À1 weight through plastic disposable syringes. 14,15 First dose was given 24 h prior to RCM injection. Isotonic saline solution (an equally volume of RCM) was administered to control group by intraperitoneal injection.…”